Published Online
on April 25, 2005

A more recent version of this article appeared on May 3, 2005

This Article Full Text (PDF) All Versions of this Article: 111/17/2219    most recent 01.CIR.0000163544.17221.BEv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, Y.-X. Articles by Light, D. R. Search for Related Content PubMed PubMed Citation Articles by Wang, Y.-X. Articles by Light, D. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Aortic Aneurysm Related Collections Animal models of human disease Apoptosis Mechanism of atherosclerosis/growth factors Other Vascular biology

Submitted on October 11, 2004
Revised on December 2, 2004
Accepted on December 8, 2004

Fasudil, a Rho-Kinase Inhibitor, Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm in Apolipoprotein E-Deficient Mice by Inhibiting Apoptosis and Proteolysis

Yi-Xin Wang MD^*, Baby Martin-McNulty BS, Valdeci da Cunha PhD, Jon Vincelette BS, Xiangru Lu MD, Qingping Feng MD, PhD, Meredith Halks-Miller MD, Mithra Mahmoudi MS, Miriam Schroeder BS, Babu Subramanyam PhD, Jih-Lie Tseng PhD, Gary D. Deng MD, PhD, Sabine Schirm PhD, Anthony Johns PhD, Katalin Kauser MD, PhD, William P. Dole MD, and David R. Light PhD

From Berlex Biosciences, Richmond, Calif (Y.-X.W., B.M.-M., V.d.C., J.V., M.H.-M., M.M., M.S., B.S., J.-L.T., G.D.D., S.S., A.J., K.K., W.P.D., D.R.L.), and the University of Western Ontario, London, Ontario, Canada (X.L., Q.F.).

^* To whom correspondence should be addressed. E-mail: jim_wang{at}berlex.com.

Background--Angiotensin II (Ang II) accelerates atherosclerosis and induces abdominal aortic aneurysm (AAA) in an experimental mouse model. Agonism of a G protein-coupled receptor by Ang II activates Rho-kinase and other signaling pathways and results in activation of proteolysis and apoptosis. Enhanced proteolysis and smooth muscle cell apoptosis are important mechanisms associated with AAA. In this study, we tested the hypothesis that fasudil, a Rho-kinase inhibitor, could attenuate Ang II-induced AAA formation by inhibiting vascular wall apoptosis and extracellular matrix proteolysis.

Methods and Results--Six-month-old apolipoprotein E-deficient mice were infused with Ang II (1.44 mg · kg^-1 · d^-1) for 1 month. Animals were randomly assigned to treatment with fasudil (136 or 213 mg · kg^-1 · d^-1 in drinking water) or tap water. Ang II infusion induced AAA formation in 75% of the mice, which was accompanied by an increase in proteolysis detected by zymographic analysis and quantified by active matrix metalloproteinase-2 activity, as well as apoptosis detected by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling and quantified by both caspase-3 activity and histone-associated DNA fragmentation. The level of DNA fragmentation in the suprarenal aorta correlated with AAA diameter. Ang II also increased atherosclerotic lesion area and blood pressure. Fasudil treatment resulted in a dose-dependent reduction in both the incidence and severity of AAA. At the higher dose, fasudil decreased AAA by 45% while significantly inhibiting both apoptosis and proteolysis, without affecting atherosclerosis or blood pressure.

Conclusions--These data demonstrate that inhibition of Rho-kinase by fasudil attenuated Ang II-induced AAA through inhibition of both apoptosis and proteolysis pathways.

Key words: angiotensin II • aortic aneurysm, abdominal • mice, knockout • apoptosis • metalloproteinases

This article has been cited by other articles:

				L.-N. Zhang, J. Vincelette, Y. Cheng, U. Mehra, D. Chen, S.-K. Anandan, R. Gless, H. K. Webb, and Y.-X. Wang Inhibition of Soluble Epoxide Hydrolase Attenuated Atherosclerosis, Abdominal Aortic Aneurysm Formation, and Dyslipidemia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1265 - 1270. [Abstract] [Full Text] [PDF]

				H.-W. Wang, P.-Y. Liu, N. Oyama, Y. Rikitake, S. Kitamoto, J. Gitlin, J. K. Liao, and W. A. Boisvert Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice FASEB J, October 1, 2008; 22(10): 3561 - 3570. [Abstract] [Full Text] [PDF]

				H. Ikeda, Y. Kume, K. Tejima, T. Tomiya, T. Nishikawa, N. Watanabe, N. Ohtomo, M. Arai, C. Arai, M. Omata, et al. Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G911 - G917. [Abstract] [Full Text] [PDF]

				P. Rivera, M. P. Ocaranza, S. Lavandero, and J. E. Jalil Rho Kinase Activation and Gene Expression Related to Vascular Remodeling in Normotensive Rats With High Angiotensin I Converting Enzyme Levels Hypertension, October 1, 2007; 50(4): 792 - 798. [Abstract] [Full Text] [PDF]

				J. Golledge, J. Muller, A. Daugherty, and P. Norman Abdominal Aortic Aneurysm: Pathogenesis and Implications for Management Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2605 - 2613. [Abstract] [Full Text] [PDF]

				H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells Hypertension, October 1, 2006; 48(4): 534 - 540. [Full Text] [PDF]

				G. Loirand, P. Guerin, and P. Pacaud Rho Kinases in Cardiovascular Physiology and Pathophysiology Circ. Res., February 17, 2006; 98(3): 322 - 334. [Abstract] [Full Text] [PDF]